SeaFort Capital Invests in Allmar to Accelerate Growth
HALIFAX, Nova Scotia, March 4, 2026 SeaFort Capital announced a majority investment in Allmar Inc., marking a significant private...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
HALIFAX, Nova Scotia, March 4, 2026 SeaFort Capital announced a majority investment in Allmar Inc., marking a significant private...
Vancouver, British Columbia, December 18, 2025 — Restart Life Sciences Corp., a Canadian-based life sciences company, has successfully closed...
